Drug-induced QT prolongation (DIQT) commonly appears in variety of pharmacological treatment and may cause severe cardiac complications such as Torsades de pointes (TdP). The lack of a centralized data resource for organizing, standardizing, and integrating drug-induced QT prolongation-related information is currently the main obstacle to further studying the underlying mechanism and developing an effective prediction strategy. The web-based application of Drug-induced QT prolongation Atlas (DIQTA) incorporated the information of the FDA-approved drug labeling, DIQT classification, post-marketing DIQT surveillance data, drug properties and pharmacogenomics data for the purpose of enhancing cardiac adverse drug reaction (ADR) management, such as dose adjustment in off-label use, therapeutic strategy optimization and artificial intelligence-based modeling for cardiotoxicity.